"The
Report Frontier Pharma: Versatile Innovation in Oncology -
Identifying and Commercializing Versatile First-in-Class Innovation
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
The oncology therapy area
comprises a large and diverse range of indications, encompassing
virtually all sites and tissues in the human body. These indications
are the leading cause of death in economically developed countries
and the second-leading cause of death in developing countries and
present a major global health burden. Across the pharmaceutical
industry as a whole, the oncology pipeline is far larger than any
other therapy area, with 6,484 products in active development across
all oncology indications, and 2,084 first-in-class products in
development across all stages.
Due to a degree of crossover
between oncology indications in terms of their underlying
pathophysiology, it is not uncommon for products being developed for
this therapy area to have developmental programs testing them across
multiple indications. Some 473 first-in-class pipeline products are
in concurrent development for two or more of the top 20 cancer sites
ranked by incidence. The most promising versatile first-in-class
molecular targets predominantly consist of receptor tyrosine kinases
and their downstream signal transduction kinases, although a number
of other cancer-related processes such as DNA repair, cancer
immunosurveillance and apoptotic pathways are also targeted.
View Report At
:http://www.marketresearchreports.biz/analysis/316439
Scope
- With 6,484 products in active development across all oncology indications, this is the largest therapy area pipeline by a considerable margin.
- What factors are driving this high level of R&D activity?
- Which indications have the highest concentration of pipeline products?
- Although the unmet need varies between and within indications, this need is primarily for improved overall survival rates in patients, particularly those at the late stage of the disease.
- Which first-in-class molecular targets appear able to best address the key unmet needs within oncology?
- The variation in molecule type has shifted away from small molecules, the dominance of which has decreased from 94% across marketed products to 49% across the pipeline.
- What are the dynamics of the remaining 51% of the pipeline?
- How does this reflect the need for novel targeted therapies?
- There has been a significant shift towards inhibitors of receptor tyrosine kinases, their ligands and signal transduction proteins, as well as drugs targeted against cancer antigens.
- What is the scientific rationale behind these targets? Across which indications are they being developed?
- How successful have drugs against these targets been?
- A number of versatile first-in-class targets appear to be particularly promising, including HER3, FGFR3, telomerase reverse transcriptase, and others.
- Why are these targets considered to be particularly promising?
- Why are these targets being developed across such a wide range of indications?
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/316439
Reasons
to buy
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options across the key oncology indications
- Acquire a detailed understanding of the 20 most common oncology indications by incidence, pinpointing the unmet needs for each indication
- Assess the market for oncology in terms of the molecular targets that are approved across multiple indications and the predominant molecule types and targets
- Analyze the oncology pipeline and stratify by stage of development, molecule type, molecular target, and first-in-class status
- Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are in development for
- Analyze the therapeutic potential and developmental footprint of versatile first-in-class targets and understand which are the most promising. Understand which targets are being developed in each indication, for how many pipeline products, and how well they align with the underlying pathophysiology of cancer
- Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals for versatile first-in-class products
- Identify versatile first-in-class pipeline products that have not been previously involved in licensing or co-development deals and are thus more likely to be available for in-licensing or co-development
Table
of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 A Large Therapy Area with
Varying Unmet Needs Across Indications 5
2.2 A Large Pipeline with a
High Degree of First-in-Class Innovation 5
2.3 A Number of Highly
Promising First-in-Class Versatile Oncology Pipeline Targets 5
3 The Case for Innovation in
the Oncology Market 6
3.1 Growing Opportunities for
Biologic Products 7
3.2 Diversification of
Molecular Targets 7
3.3 Innovative First-in-Class
Product Developments Remain Attractive 7
3.4 Regulatory and
Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 Report Guidance 9
4 Clinical and Commercial
Landscape 10
4.1 Therapy Area Overview 10
4.1.1 Epidemiology 10
4.1.2 Etiology 14
4.1.3 Pathophysiology 15
4.1.4 Diagnosis 21
4.1.5 Prognosis and Disease
Staging 22
4.2 Treatment Options 24
4.2.1 Surgery and Radiation
Therapy 24
4.2.2 Chemotherapy 27
4.2.3 Hormonal Therapies 28
4.2.4 Targeted Therapies 29
4.3 Overview of Marketed
Products for Oncology 30
4.4 Current Unmet Needs across
the Oncology Markets 32
5 Assessment of Pipeline
Product Innovation 34
5.1 Oncology Pipeline by Phase,
Molecule Type and Molecular Target 35
5.2 Comparative Distribution of
Programs between the Oncology Market and Pipeline by Therapeutic
Target Family 38
5.3 First-in-Class and
Versatile Pipeline Programs 38
5.3.1 First-in-Class Oncology
Products by Phase, Molecule Type and Molecular Target 40
5.3.2 Versatility of
First-in-Class Pipeline Products 43
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment